MetaCap

Acumen Pharmaceuticals (ABOS) vs aTyr Pharma (ATYR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

aTyr Pharma (ATYR) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, gaining 474.4% versus a loss of 88.1%. Over five years, ATYR leads with a -52.6% price change compared with -97.7% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $9.7 million), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABOS-88.12%ATYR+474.44%
+1096%+476%-145%
Nov 21, 20251 yearNov 20, 2026
ABOS-98.11%ATYR-53.41%
+7%-48%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABOS versus ATYR key metrics
MetricABOSATYR
Share price$0.1865$3.82
Market cap$13.49M$9.74M
1-day change-3.52%+3.52%
YTD return-91.16%+387.87%
1-year return-88.12%+474.44%
5-year return-97.74%-52.61%
EPS (TTM)$-1.55$-21.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$190.00K
Revenue growth (YoY)—-19.15%
Net income (latest FY)$-121.33M$-74.12M
Operating margin—-40856.32%
Net margin—-39009.47%
52-week high$3.60$44.40
52-week low$0.16$3.69
Distance from 52-week high-94.82%-91.40%
Analyst consensusstrong_buybuy
Avg. price target upside+3975.07%-25.13%
Average volume2.73M115.38K
Shares outstanding72.33M2.55M
Employees6058
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATYR has outperformed ABOS by 562.6 percentage points over the past year.

About Acumen Pharmaceuticals

ABOS stock →

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

About aTyr Pharma

ATYR stock →

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees

ABOS vs ATYR FAQ

Which is bigger, Acumen Pharmaceuticals or aTyr Pharma?

Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $9.74M for aTyr Pharma (ATYR).

Which stock has performed better over the past year, ABOS or ATYR?

ATYR returned +474.44% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.

Are Acumen Pharmaceuticals and aTyr Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons